Abbreviated name: TDF
Synonyms: (R)-PMPA | PMPA | tenofovir (anhydrous)
tenofovir is an approved drug
Compound class:
Synthetic organic
Comment: Tenofovir is a nucleotide reverse transcriptase inhibitor (NtRTI) antiretroviral compound. The R-enantiomer, as shown here, is more effective at inhibiting retroviruses than the S-enantiomer [1]. Tenofovir has poor oral bioavailability and is delivered as either the prodrug tenofovir disoproxil fumarate (Viread®) or tenofovir alafenamide fumerate (Vemlidy®).
|
|
Bioactivity Comments |
OAT1 and OAT3 in the basal membrane actively transport 20-30% of tenofovir into proximal tubule cells [3]. ABCC2 (MRP2) and ABCC4 (MRP4) at the apical surface secrete tenofovir into the tubular lumen [5]. |
Transporters Moving this Compound Across a Lipid Membrane | ||||||||||||||||||||
|
Targets where the ligand is described in the comment field | |
Target | Comment |
CoV RNA-dependent RNA polymerase | The conservation of RdRP catalytic domain between different RNA viruses endows inhibitors that were designed against other viral pathogens with activity against the SARS coronaviruses. Viral RdRP is the molecular target of nucleotide-based broad-spectrum antiviral compounds like remdesivir, tenofovir and ribavirin [4,6,8]. |